Abrysvo

Abrysvo is Pfizer's RSV (respiratory syncytial virus) vaccine, the world's first approved for use in pregnant women to protect newborns from RSV lower respiratory tract infection during their first six months of life via maternal antibodies; it is intended for administration between 32 and 36 weeks of gestation. Offered by VuRoyal (SuQian) Pharmaceutical Company LLC, which does not manufacture it directly and does not provide free samples, it is contraindicated for those allergic to its ingredients and vaccination should be postponed during fever or acute infection. It is distributed into North America and Central/South America.